InvestSMART

EMvision Medical Devices Limited (ASX:EMV)

ALERT: Price-sensitive ASX Announcement for EMV
Current share price for EMV : $1.725 -0.025 (-1.43%)+
Announcement
Release
23 Feb 2026 9:20AM
Price at Release
$1.750
Full Release
download
Summary
The half-year report for EMVision Medical Devices Limited ending 31 December 2025 highlights the company's focus on research and development of neurodiagnostic technology, specifically portable brain scanners for stroke diagnosis. Despite a loss of $3,967,663, the company invested heavily in R&D and employee expenses due to expanded clinical trials and pilot manufacturing activities. Key financials include a net asset position of $19,741,470, with significant cash inflows from share issues. The report also details non-dilutive funding from the NSW Medical Devices Fund and other grants totaling over $5 million, supporting clinical studies and product development. The company faces challenges typical to medical device development, including regulatory approvals and securing patent protections, but remains confident due to its experienced team and strong funding position.
Key Points
  • Net loss for half-year: $3,967,663
  • Significant R&D and employee expenses
  • Cash position at year-end: $17,545,236
  • Funding from NSW Medical Devices Fund and other grants
  • Focus on portable brain scanners for stroke
  • Pilot manufacturing and clinical trial expansions
  • Non-dilutive funding and grants secured
  • Challenges include regulatory approvals and patent protections
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.